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Background: Diabetes is a major comorbidity in insomnia patients. The efficacy and safety of 
prolonged-release melatonin 2 mg in the treatment of glucose, lipid metabolism, and sleep was 
studied in 36 type 2 diabetic patients with insomnia (11 men, 25 women, age 46–77 years).
Methods: In a randomized, double-blind, crossover study, the subjects were treated for 3 weeks 
(period 1) with prolonged-release melatonin or placebo, followed by a one-week washout period, 
and then crossed over for another 3 weeks (period 2) of treatment with the other preparation. 
All tablets were taken 2 hours before bedtime for a period of 3 weeks. In an extension period of 
5 months, prolonged-release melatonin was given nightly to all patients in an open-label design. 
Sleep was objectively monitored in a subgroup of 22 patients using wrist actigraphy. Fasting 
glucose, fructosamine, insulin, C-peptide, triglycerides, total cholesterol, high-density and 
low-density lipoprotein cholesterol, and some antioxidants, as well as glycosylated   hemoglobin 
(HbA1c) levels were measured at baseline and at the end of the study. All concomitant medica-
tions were continued throughout the study.
Results: No significant changes in serum glucose, fructosamine, insulin, C-peptide, antioxidant 
levels or blood chemistry were observed after 3 weeks of prolonged-release melatonin treatment. 
Sleep efficiency, wake time after sleep onset, and number of awakenings improved significantly 
with prolonged-release melatonin as compared with placebo. Following 5 months of prolonged-
release melatonin treatment, mean HbA1c (±standard deviation) was significantly lower than at 
baseline (9.13% ± 1.55% versus 8.47% ± 1.67%, respectively, P = 0.005).
Conclusion: Short-term use of prolonged-release melatonin improves sleep maintenance in type 
2 diabetic patients with insomnia without affecting glucose and lipid metabolism.   Long-term 
prolonged-release melatonin administration has a beneficial effect on HbA1c, suggesting 
improved glycemic control.
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Introduction
Diabetes mellitus is a chronic age-related disease affecting an increasing number of 
patients worldwide and is currently reaching epidemic proportions.1 Several studies 
have suggested a direct association between diabetes and sleep disturbances.2–7 Primary 
sleep disorders have been suggested to promote development of the metabolic syndrome 
that is strongly associated with increased type 2 diabetes and cardiovascular risk.7 On 
the other hand, uncontrolled diabetes may adversely affect sleep quality nonspecifi-
cally, as a result of night-time thirst, a sensation of dryness, and nocturia, symptoms 
of hypoglycemia (sweating and tachycardia), stress, anxiety, and depression. All of 
these factors may impair good sleep at night.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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Melatonin (N-acetyl-5-methoxytryptamine), the major 
hormone produced nocturnally by the pineal gland, is a sleep 
regulator and signal of darkness in humans. The circadian 
rhythm of synthesis and secretion of melatonin is closely 
associated with the sleep rhythm in both sighted and blind 
subjects.8 Daytime administration of exogenous melatonin 
(when it is not present endogenously) promotes sleep in 
humans8 and results in sleep-like brain activity patterns at 
specific areas such as the precuneus and hippocampus.9,10 
Endogenous melatonin levels decrease with age,11 and 
this decline may contribute to the common complaint of 
poor sleep quality in elderly people.12 Abnormalities of the 
  nocturnal melatonin profile have also been described in 
diabetic patients, mainly in those suffering from   diabetic 
neuropathy.13 Post mortem studies have indicated an 
association between diabetes mellitus and decreased mela-
tonin secretion.14 Melatonin deficiency deprives the brain of 
an important regulator of sleep and time cue to the internal 
circadian clock,15 and may thus exacerbate sleep problems 
in diabetic patients.
There is also a growing body of evidence suggesting 
a link between disturbance in melatonin production and 
impaired insulin, glucose, lipid metabolism, and antioxidant 
capacity.16–19 Furthermore, melatonin has been found to 
influence insulin secretion both in vivo and in vitro,18 and 
night-time melatonin levels are reportedly related to night-
time insulin concentrations in patients with the metabolic 
syndrome.19 In several recent studies, a single nucleotide 
polymorphism of the human melatonin receptor 1B has 
been described as being causally linked to increased risk of 
developing type 2 diabetes.20–22 All these data suggest that 
endogenous as well as exogenous melatonin may play a role 
in improving diabetic control.
Melatonin has a very short half-life of 40–50 minutes,23 
and is quickly eliminated from the circulation, but 
physiological levels are maintained throughout the night 
as a result of continuous secretion by the pineal gland. 
Prolonged-release melatonin 2 mg is a new drug licensed to 
treat primary insomnia in patients aged 55 years and older. 
It exerts its effects by mimicking the release pattern of 
endogenous melatonin in the brain. In randomized, placebo-
controlled clinical trials, prolonged-release melatonin 2 mg 
significantly improved sleep latency, quality of sleep, and 
morning alertness, as compared with placebo in patients 
aged 55 years and older,24–27 and improved sleep maintenance 
assessed by actigraphy.28
The aim of the current study was to investigate the 
effect of prolonged-release melatonin 2 mg administered 
at 9–11 pm for 3 weeks on glucose and lipid metabolism 
in community-dwelling diabetics suffering from insomnia. 
The effects of this treatment on sleep parameters were 
assessed in a subgroup of the patients using actigraphy. An 
extended period of 5 months of open-label, prolonged-release 
melatonin administration followed to evaluate the effects of 
prolonged-release melatonin on glycosylated hemoglobin 
(HbA1c) levels over a longer period of treatment, as an 
indicator of diabetic control.29
Methods
The study was performed in accordance with the World 
Medical Assembly guidelines, ie, the latest version of 
the Declaration of Helsinki, and the standard operating 
procedures of Neurim Pharmaceuticals Ltd. All patients 
were given full details of the study in both verbal and written 
form by the investigator. Each patient gave their written 
informed consent for study participation according to Good 
Clinical Practice rules. The study protocol was approved 
by the Ethics Committee of the E Wolfson Medical Center, 
Holon, Israel.
Study design
In a randomized, double-blind, crossover design, the subjects 
were given tablets of either prolonged-release melatonin 
2 mg (Circadin®, Rad Neurim Pharmaceuticals EEC Ltd) 
or an identical-looking placebo. The tablets were taken 
2 hours before bedtime for a period of 3 weeks (period 1). 
This was followed by a washout period of 1 week and then 
by another 3-week period of treatment with the alternative 
preparation (period 2). Patients, investigators, and coworkers 
were blinded to the drug given during the crossover, double-
blind treatment periods. Access to the randomization code 
was given to the pharmacist who prepared the tablets in con-
tainers. During the extension period of 5 months (period 3) 
prolonged-release melatonin was given nightly to all patients 
in an open-label manner. Treatment codes were opened after 
study completion and final entry of all study data.
Participants
Eligible patients were men and women diagnosed and treated 
for type 2 diabetes who also complained of insomnia. Patients 
with liver or renal disease (serum creatinine $1.5 mg/dL) 
were excluded. All concomitant medications were continued 
during the trial, and included metformin, sulfonylureas, 
glucosidase inhibitors, glitazones, insulin, statins, fibrates, 
angiotensin-converting enzyme inhibitors, calcium channel 
blockers, alpha-blockers, beta-blockers, antiplatelet agents, Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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antiarrhythmic drugs, nitrates, phosphodiesterase inhibitors, 
bronchodilators, and antidepressants.
evaluation of sleep parameters
A subset of patients in the study were assigned (based on 
availability of equipment) to undergo recording of their 
activity-rest patterns by wrist actigraphy (SomnitorTM, 
  Neurim Pharmaceuticals Ltd, Tel Aviv, Israel30) while 
sleeping at home. Motion recordings were analyzed as 
  previously described24 to evaluate total sleep time (time spent 
asleep after sleep onset), sleep efficiency (total sleep time 
divided by time in bed multiplied by 100%), wake after sleep 
onset (sum of mid sleep arousal times after sleep onset), 
number of awakenings (between sleep onset and offset), 
and sleep latency (the lag period between entering bed and 
sleep onset). Changes in each parameter averaged over 3 
consecutive nights from the placebo run-in period (baseline) 
to the end of 3 weeks of treatment were calculated for each 
patient.
Laboratory assessment
Fasting blood was withdrawn from all patients for routine 
hematologic and biochemistry evaluation on the morning 
before randomization, the morning following the last night 
of treatment periods 1 and 2, and the morning following the 
end of period 3. These tests included complete blood count, 
serum urea, creatinine, sodium, potassium, chloride, calcium, 
phosphate, total protein, albumin, globulin, bilirubin, alkaline 
phosphatase, glutamic pyruvic transaminase, glutamic 
oxaloacetic transaminase, lactic dehydrogenase, and creatine 
phosphokinase. In the double-blind periods, glycemic control 
and lipid metabolism were evaluated by assessment of 
fasting glucose, fructosamine, HbA1c, insulin (for patients 
not treated with insulin), C-peptide, triglycerides, and 
cholesterol (total, high-density and low-density lipoprotein). 
Several antioxidants were also assessed in plasma, ie, malone 
dialdehyde, conjugated dienes, catalase, and glutathione 
peroxidase and reductase. The patients were then given a 
standard meal and postprandial blood sampling for serum 
glucose, insulin, and C-peptide was performed two hours 
later. Laboratory testing of HbA1c and postprandial glucose 
was performed again following 5 months of prolonged-
release melatonin treatment.
Statistical analysis
The data collected were analyzed using SAS version 6.10 
(SAS, Cary, NC). The effects of prolonged-release melatonin 
on each of the laboratory parameters were compared using 
a 2 × 2 mixed design analysis of covariance. The within-
subject factor used was treatment (placebo versus prolonged-
release melatonin) while the between-subject factor was 
order of administration (placebo then prolonged-release 
melatonin versus prolonged-release melatonin then pla-
cebo). The covariate used was the measure of the respective 
  parameter at baseline (prestudy). The effect of prolonged-
release   melatonin on sleep parameters was evaluated using 
a 2 × 2 mixed design analysis of variance for repeated 
  measurement. In addition, the interaction between the effects 
of prolonged-release melatonin and disease was assessed by 
analyses of covariance where the between-subject factor was 
insulin treatment for type 2 diabetes.
Results
A total of 36 independently living type 2 diabetic patients 
(16 on oral hypoglycemic agents and 20 on insulin) 
who also complained of insomnia were entered into the 
study. Eleven were men and 25 were women, and mean 
age ± standard deviation was 63 ± 8 (range 46–77) years. 
All 36 patients completed the randomized crossover and 
extension parts of the study. Sleep quality was recorded 
by wrist actigraphy in a subgroup of 22 patients (seven 
men and 15 women). Statistical analyses of the efficacy 
of prolonged-release melatonin on sleep were therefore 
performed only in these 22 diabetic patients. One or both 
HbA1c measures were lacking in seven patients. Thus, 
statistical analyses of the long-term effects of prolonged-
release melatonin on HbA1c were based on results obtained 
from 29 diabetic patients (10 men, 19 women), of whom 12 
were treated with oral hypoglycemic agents and 17 were 
on insulin (see Figure 1 for full details).
A significant effect of order of administration (F(1,24) = 6.88, 
P , 0.05) and a significant interaction between treatment 
and order of administration (F(1,23) = 5.44, P , 0.05) were 
observed for fasting glucose; the mean serum glucose level on 
prolonged-release melatonin in the second crossover period 
was significantly lower than that during the first crossover 
period. No significant treatment effect on fasting glucose was 
found compared with placebo. No other significant treatment 
order effects in the laboratory parameters were found, nor any 
significant interactions between treatment and order.
The overall safety and tolerability results as well as diabetes 
status were similar in all treatment periods.   Prolonged-release 
melatonin 2 mg had no significant effect on routine   laboratory 
tests, glucose and lipid metabolism, or antioxidant levels. 
  However, there was a significant decrease in HbA1c concen-
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  following the five-month extension period (t(29) = 3.29, 
P = 0.005, t-test for dependent samples). Of the 29 patients in 
whom HbA1c data on both time points were available, HbA1c 
levels decreased by 1% or more in 11 and increased in 1; the 
mean decrease in HbA1c was 0.66% ± 1.15% regardless of 
the order of treatment in the randomization phase. A t-test for 
independent samples performed on the reduction in HbA1c 
from prestudy levels to those after 5 months on prolonged-
release melatonin, indicated that the reduction in HbA1c was 
not significantly different in type 2 diabetics treated or not 
treated by insulin (P = 0.68).
The effects of 3 weeks of prolonged-release melatonin 
compared with placebo on sleep parameters are depicted in 
Table 1. Statistically significant improvements in several 
Assessed for eligibility (n = 36) 
Excluded from HbA1c analysis
(n = 7)
(missed one or both HbA1c blood
sampling) 
Completed assessment of HbA1c
plasma levels (n = 29)
Completed the double-blind crossover
period with actigraphy (n = 22)
Completed the double-blind crossover
period without actigraphy (n = 14) 
Completed five months of open-label PRM treatment (n = 36) 
Randomized to three weeks of crossover PRM/placebo treatment 
Figure 1 Overall patient disposition. Analysis of the short-term period included eligible patients who completed three weeks of double-blind treatment with prolonged-
release melatonin or placebo. Analysis of the long-term period included patients treated open-label with prolonged-release melatonin for 5 months. Analyses of actigraphic 
motion recordings included eligible patients who completed 3 weeks of treatment with prolonged-release melatonin and placebo and provided actigraphy data by the end 
of the treatment period.
Abbreviation: PrM, prolonged-release melatonin.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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sleep parameters were found for prolonged-release melatonin 
compared with placebo (Table 1). Of the 22 patients in whom 
sleep assessments were performed, 12 had a net improvement 
of more than 3% in sleep efficiency on prolonged-release 
melatonin as compared with placebo, and 15 had a net 
improvement of at least 25% in wake after sleep onset. In 12 
patients, the number of awakenings was improved by at least 
25%, while only seven showed little or no improvement in 
any of the sleep parameters on prolonged-release melatonin 
compared with placebo. No significant treatment order effects 
or interactions between treatment and order were found in 
the sleep parameters.
Improvement in sleep parameters in the double-blind 
period did not predict change in HbA1c during the long-term 
period, and improvement in HbA1c levels was found both in 
patients in whom sleep quality was or was not improved.
No serious adverse events were reported. An adverse 
experience was reported seven times on prolonged-release 
melatonin treatment, ie, insomnia (n = 2), abnormal thoughts 
(n = 1), taste aversion (n = 1), and sexual dysfunction (n = 3), 
and five times on placebo treatment, ie, somnolence (n = 3), 
libido increase (n = 2), and sexual dysfunction (n = 1).
Discussion
These results show that prolonged-release melatonin is safe 
in diabetic patients, having no adverse effects on glucose 
and lipid metabolism or other routine biochemical tests, and 
no other adverse events during short-term (3 weeks) and 
long-term use. No interaction with any of the   medications 
 frequently used in diabetic patients was observed (ie, 
  metformin, sulfonylureas, thiazolidinediones, peroxisome-
proliferator activated receptors agonists, insulin, fibrates and 
other lipid-lowering agents, angiotensin-converting inhibi-
tors, calcium antagonists, beta-blockers, anticoagulants, and 
serotonin reuptake inhibitors). Importantly, prolonged-release 
melatonin did not affect C-peptide levels, suggesting that it 
had no effect on the release of insulin in these patients.
It was shown that glucose tolerance and insulin sensitivity 
were both reduced as compared with placebo following 
a single oral administration of melatonin 1 mg in 22 
postmenopausal nondiabetic women. The authors suggested 
that melatonin should be avoided in diabetes.31 Our findings 
do not support this notion, and indicate that prolonged-
release melatonin does not impair insulin action or glucose 
tolerance in diabetic patients, whether used in the short term 
or long term. On the contrary, we have shown improved 
glycemic control upon long-term use of prolonged-release 
melatonin.
In two other studies, the combination of melatonin and 
zinc acetate alone or in combination with metformin was 
found to improve fasting and postprandial glycemic control 
in type 2 diabetic patients.32 Melatonin was not given alone 
in these studies, and it is therefore impossible to evaluate its 
specific effect on glycemic control. However, these results 
are in line with our data and support our findings regarding 
the safety of melatonin in diabetic patients.
Our findings of improved diabetic control with prolonged-
release melatonin are also compatible with those of some 
animal studies. Long-term administration of time-release 
melatonin pellets (1.1 mg/day for 30 weeks) reduced 
the development of hypertriglyceridemia, hyperinsulinemia, 
and hyperleptinemia, and restored normal ratios of 
20:3n–6/20:4n–6 phospholipids in a rat model of diabetes.33 
This finding suggests that long-term melatonin administration 
may slow down age-related deterioration in glucose and 
lipid metabolism. The decrease in HbA1c may be due to 
better compliance with diet and treatment as a result of 
participation in the study. Alternatively, it may be the result 
of an antistress effect of melatonin causing attenuation of 
glucose fluctuations.
Prolonged-release melatonin improved sleep maintenance 
in comparison with placebo, as indicated by improvements 
in sleep efficiency, wake after sleep onset, and number of 
awakenings. The effects were consistent with those seen in 
Table 1 Actigraphy-derived sleep parameters (mean ± standard deviation) following 3 weeks of administration of prolonged-release 
melatonin or placebo (crossover, n = 22)
Parameter Placebo PRM Order effect  
P value
Treatment by order  
P value
Treatment effect   
P value
Sleep efficiency (%)   79.2 ± 9.8   83.0 ± 11.7 0.86 0.31 ,0.04
Sleep latency (minutes)   18.1 ± 13.2   20.7 ± 18.0 0.66 0.90 0.36
Wake after sleep onset (minutes)   66.3 ± 38.7   38.0 ± 22.1 0.58 0.85 ,0.001
Total sleep time (minutes) 366.1 ± 66.2 355.1 ± 74.5 0.84 0.09 0.41
number of awakenings   16.5 ± 8.5   10.8 ± 5.4 0.28 0.35 ,0.003
Abbreviation: PrM, prolonged-release melatonin.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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placebo-controlled studies of prolonged-release melatonin 
in patients suffering from insomnia.24–28 Sleep latency did 
not improve on prolonged-release melatonin as   compared 
with placebo, perhaps because the mean sleep latency in 
this   population (18.1 ± 13.2 minutes) was only slightly 
longer than 15 minutes (a value considered normal). We 
did not find any significant differences in glucose or lipid 
metabolism during the 3 weeks of treatment with prolonged-
release   melatonin. Therefore, the effect on sleep maintenance 
is probably directly linked to the specific sleep-promoting 
effects of melatonin rather than improvement in diabetes 
control. Because the improvement in sleep in diabetic patients 
was not predictive of reduction in HbA1c, the effect of pro-
longed-release melatonin on HbA1c is probably not related 
to the improvement in sleep, but rather reflects a mechanism 
that involves glucose metabolism per se. Of 13 patients who 
responded to prolonged-release melatonin with an increase 
in sleep efficiency of 3% or more, seven were concomitantly 
on metformin, five on sulfonylureas, five on both metformin 
and sulfonylureas, one on pioglitazone, and seven were on 
insulin. Hence, the soporific activity of prolonged-release 
melatonin is probably independent of concomitant antidi-
abetic drug effects.
Melatonin may act at the level of the circadian clock 
in the suprachiasmatic nuclei of the hypothalamus to 
improve the robustness of the circadian system.15 An 
increase in   endogenous glucose production is a major con-
tributor to   fasting morning hyperglycemia in type 2 diabetes. 
Endogenous glucose production and gluconeogenesis display 
diurnal rhythms that drive fasting hyperglycemia and are 
absent in healthy control subjects.34 Melatonin is closely 
related to endogenous glucose production, but its secretion 
is attenuated in diabetes.34 Diurnal variations in endogenous 
glucose production in diabetes may be related to reduction 
in the robustness of the suprachiasmatic nuclei in the hypo-
thalamus in diabetes that may be responsible, at least in part, 
for low melatonin production in these patients. Timing and 
dose-controlled exogenous hormone supplementation aimed 
at normalizing melatonin levels have been shown to affect 
the circadian pacemaker by modifying the internal clock in 
humans.8 Melatonin treatment may thus reinforce circadian 
control of glucose metabolism and subsequently stabilize 
endogenous glucose production, reduce serum glucose, and 
eventually contribute to better glycemic control.
Long-term administration of low-dose, prolonged-release 
melatonin 2 mg/day was associated with a significant reduc-
tion in HbA1c in type 2 diabetic patients. Because a 0.5% 
HbA1c difference between successive results is considered 
a clinically relevant change, our finding of a mean decrease 
of 0.66% ± 1.15% in HbA1c is both statistically significant 
and of clinical importance.35 It has been reported that each 
1% reduction in HbA1c is associated with a risk reduction 
of 21% for any end point related to diabetes, suggesting 
that even a modest reduction in glycemia has the potential 
to prevent deaths from complications related to diabetes.36 
In the current study, more than one third of patients showed 
decreased HbA1c levels of 1% or more. Although no   parallel 
placebo treatment was used during this period, this obser-
vation may suggest some antihyperglycemic activity for 
melatonin in humans.
Two major limitations of our study are that the long-
term treatment was not placebo-controlled and the circadian 
rhythm of glucose production was not measured. Further 
studies to clarify the involvement of circadian modulation 
in improvement of diabetic control by prolonged-release 
melatonin, and the long-term nature of these effects, are 
warranted.
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